Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Drug Research

Volumn 67, Issue 4, 2017, Pages 244-251

  Panahi, Yunes ^a   Kianpour, Parisa ^b   Mohtashami, Reza ^a   Jafari, Ramezan ^a   Simental Mendía, Luis E ^c   Sahebkar, Amirhossein ^d,e  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

curcuminoids; liver; non alcoholic fatty liver disease; randomized controlled trial; steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CURCUMIN; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; PLACEBO; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DRUG DOSAGE FORM; POLYPHENOL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIET; DISEASE SEVERITY; DOPPLER ULTRASONOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; LIPID STORAGE; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ULTRASOUND SCANNER; WAIST CIRCUMFERENCE; BLOOD; DIETARY SUPPLEMENT; DRUG DOSAGE FORM; DRUG EFFECTS; LIPID METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CURCUMIN; DIETARY SUPPLEMENTS; DOSAGE FORMS; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYPHENOLS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 85011672061     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0043-100019     Document Type: Article

References (70)

1. Williamson R M Price J F Glancy S et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study Diabetes Care 2011 34 1139 1144 doi:10.2337/dc10-2229
2. Clark J M Diehl A M Hepatic steatosis and type 2 diabetes mellitus Curr Diab Rep 2002 2 210 215
3. Bedogni G Miglioli L Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 2005 42 44 52
4. Browning J D Szczepaniak L S Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 2004 40 1387 1395
5. Vernon G Baranova A Younossi Z M Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 2011 34 274 285 doi:10.1111/j.1365-2036.2011.04724.x
6. Solga S F Diehl A M Gut flora-based therapy in liver disease? The liver cares about the gut Hepatology 2004 39 1197 1200
7. Farrell G C Larter C Z Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 2006 43 S99 S112
8. Adams L A Lymp J F St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 2005 129 113 121
9. Day C P James O F Steatohepatitis: a tale of two “hits”? Gastroenterology 1998 114 842 845
10. Gupta S C Kismali G Aggarwal B B Curcumin, a component of turmeric: from farm to pharmacy Biofactors 2013 39 2 13 doi:10.1002/biof.1079
11. Oetari S Sudibyo M Commandeur J N et al. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver Biochem Pharmacol 1996 51 39 45
12. Huang M T Lysz T Ferraro T et al. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis Cancer Res 1991 51 813 819
13. Rao C V Rivenson A Simi B et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound Cancer Res 1995 55 259 266
14. Panahi Y Ghanei M Bashiri S et al. Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled Trial Drug Res (Stuttg) 2015 65 567 573 doi:10.1055/s-0034-1389986
15. Sahebkar A Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013 39 197 208 doi:10.1002/biof.1062
16. Panahi Y Hosseini M S Khalili N et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis Clin Nutr 2015 34 1101 1108 doi:10.1016/j.clnu.2014.12.019
17. Panahi Y Saadat A Beiraghdar F et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial Phytother Res 2014 28 1461 1467 doi:10.1002/ptr.5149
18. Panahi Y Sahebkar A Parvin S et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications Ann Clin Biochem 2012 49 580 588 doi:10.1258/acb.2012.012040
19. Panahi Y Rahimnia A R Sharafi M et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial Phytother Res 2014 28 1625 1631 doi:10.1002/ptr.5174
20. Esmaily H Sahebkar A Iranshahi M et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial Chin J Integr Med 2015 21 332 338 doi:10.1007/s11655-015-2160-z
21. Panahi Y Badeli R Karami G R et al. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder Phytother Res 2015 29 17 21 doi:10.1002/ptr.5211
22. Zabihi NA, Pirro M, Johnston TP et al. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des 2016 [Epub ahead of print] PubMed PMID:27748192
23. Khonche A Biglarian O Panahi Y et al. Adjunctive therapy with curcumin for peptic ulcer: a randomized controlled trial Drug Res (Stuttg) 2016 66 444 448
24. Shehzad A Lee Y S Curcumin multiple molecular targets mediate multiple pharmacological actions-A review Drugs Future 2010 35 113 119
25. Ghandadi M, Sahebkar A. Curcumin: An effective inhibitor of interleukin-6. Curr Pharm Des 2016 [Epub ahead of print] PubMed PMID: 27719643
26. Karimian M S Pirro M Majeed M et al. Curcumin as a natural regulator of monocyte chemoattractant protein-1 Cytokine Growth Factor Rev. 2016 pii: S1359-6101(16)30131-9 10.1016/j.cytogfr.2016.10.001
27. Panahi Y Hosseini M S Khalili N et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial Biomed Pharmacother 2016 82 578 582 doi:10.1016/j.biopha.2016.05.037
28. Sahebkar A Cicero A F Simental-Mendía L E et al. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis of randomized controlled trials Pharmacol Res 2016 107 234 242 doi: doi:10.1016/j.phrs.2016.03.026 Review
29. Momtazi A A Shahabipour F Khatibi S et al. Curcumin as a MicroRNA regulator in cancer: a review Rev Physiol Biochem Pharmacol 2016 171 1 38
30. Na L X Li Y Pan H Z et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial Mol Nutr Food Res 2013 57 1569 1577 doi:10.1002/mnfr.201200131
31. Chuengsamarn S Rattanamongkolgul S Luechapudiporn R et al. Curcumin extract for prevention of type 2 diabetes Diabetes Care 2012 35 2121 2127 doi:10.2337/dc12-0116
32. Ramirez-Tortosa M C Ramirez-Tortosa C L Mesa M D et al. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha Free Radic Biol Med 2009 47 924 931
33. Bradford P G Curcumin and obesity Biofactors 2013 39 78 87 doi:10.1002/biof.1074
34. Panahi Y Sahebkar A Amiri M et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial Br J Nutr 2012 108 1272 1279
35. Sahebkar A Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis Phytother Res 2014 28 633 642 doi:10.1002/ptr.5045
36. Kang H C Nan J X Park P H et al. Curcumin inhibits collagen synthesis and hepatic stellate cell activation in-vivo and in-vitro Journal of Pharmacy and Pharmacology 2002 54 119 126
37. Sahebkar A Mohammadi A Atabati A et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals Phytother Res 2013 27 1883 1888 doi:10.1002/ptr.4952
38. Panahi Y Alishiri G H Parvin S et al. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized Controlled Trial J Diet Suppl 2016 13 209 220 doi:10.3109/19390211.2015.1008611
39. Panahi Y Ghanei M Hajhashemi A et al. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: A randomized controlled trial J Diet Suppl 2016 13 93 105 doi:10.3109/19390211.2014.952865
40. Hasan S T Zingg J M Kwan P et al. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice Atherosclerosis 2014 232 40 51
41. Öner-İyidoğan Y Koçak H Seyidhanoğlu M et al. Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet J Physiol Biochem 2013 69 677 686
42. Mohammadi A Sahebkar A Iranshahi M et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial Phytother Res 2013 27 374 379 doi:10.1002/ptr.4715
43. Sahebkar A Curcuminoids for the management of hypertriglyceridaemia Nat Rev Cardiol 2014 11 123 doi:10.1038/nrcardio.2013.140-c1
44. Sahebkar A Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights Basic & Clinical Pharmacology & Toxicology 2014 114 437 438 doi:10.1111/bcpt.12212
45. Panahi Y Khalili N Hosseini M S et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial Complement Ther Med 2014 22 851 857 doi:10.1016/j.ctim.2014.07.006
46. Sahebkar A Chew G T Watts G F Recent advances in pharmacotherapy for hypertriglyceridemia Prog Lipid Res 2014 56 47 66 doi:10.1016/j.plipres.2014.07.002
47. Semalty A Semalty M Rawat M S et al. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals Fitoterapia 2010 81 306 314 doi:10.1016/j.fitote.2009.11.001
48. Um M Y Hwang K H Ahn J et al. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase Basic Clin Pharmacol Toxicol 2013 113 152 157 doi:10.1111/bcpt.12076
49. Aggarwal B B Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals Annu Rev Nutr 2010 30 173 199 doi:10.1146/annurev.nutr.012809.104755
50. Vizzutti F Provenzano A Galastri S et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis Lab Invest 2010 90 104 115 doi:10.1038/labinvest.2009.112
51. Tang Y Zheng S Chen A Curcumin eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling Endocrinology 2009 150 3011 3020 10.1210/en.2008-1601
52. Nanji A A Jokelainen K Rahemtulla A et al. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat Hepatology 1999 30 934 943
53. Nabavi S F Eslami S Moghaddam A H et al. Protective effects of curcumin against fluoride-induced oxidative stress in the rat brain Neurophysiology 2011 43 287 291
54. Nabavi S F Nabavi S M Abolhasani F et al. Cytoprotective effects of curcumin on sodium fluoride-induced intoxication in rat erythrocytes Bull Environ Contam Toxicol 2012 88 486 490 doi:10.1007/s00128-011-0495-5
55. Tiniakos D G Vos M B Brunt E M Nonalcoholic fatty liver disease: pathology and pathogenesis Annu Rev Pathol 2010 5 145 171 doi:10.1146/annurev-pathol-121808-102132
56. Brunt E M Pathology of nonalcoholic fatty liver disease Nat Rev Gastroenterol Hepatol 2010 7 195 203 doi:10.1038/nrgastro.2010.21
57. Brunt E M Histological assessment of nonalcoholic fatty liver disease in adults and children Clin Liver Dis 2012 1 107 110
58. Puri P Sanyal A J Nonalcoholic fatty liver disease: definitions, risk factors, and workup Clin Liver Dis 2012 1 98 102
59. Ramirez-Tortosa M C Ramirez-Tortosa C L Mesa M D et al. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha Free Radic Biol Med 2009 47 924 931 doi:10.1016/j.freeradbiomed.2009.06.015
60. Leclercq I A Farrell G C Sempoux C et al. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice J Hepatol 2004 41 926 934
61. Wang Y Li J Zhuge L et al. Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine-and choline-deficient diet Exp Ther Med 2014 7 663 668
62. Nseir W Hellou E Assy N Role of diet and lifestyle changes in nonalcoholic fatty liver disease World J Gastroenterol 2014 20 9338 9344
63. Finelli C Tarantino G Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol 2012 18 6790 6800 doi:10.3748/wjg.v18.i46.6790
64. Huang W C Chiu W C Chuang H L et al. Effect of curcumin supplementation of physiological fatigue and physical performance in mice Nutrients 2015 7 905 921
65. Nabavi S F Daglia M Moghaddam A H et al. Curcumin and liver disease: from chemistry to medicine Comprehensive Reviews in Food Science and Food Safety. 2014 13 62 77 doi:10.1111/1541-4337.12047
66. Goel A Kunnumakkara A B Aggarwal B B Curcumin as “Curecumin”: from kitchen to clinic Biochem Pharmacol 2008 75 787 809
67. Hatcher H Planalp R Cho J et al. Curcumin: from ancient medicine to current clinical trials Cell Mol Life Sci 2008 65 1631 1652 doi:10.1007/s00018-008-7452-4
68. Soni K B Kuttan R Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers Indian J Physiol Pharmacol 1992 36 273 275
69. Osawa H Mori Y Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes J Clin Ultrasound 1996 24 25 29
70. Hernaez R Lazo M Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis Hepatology 2011 54 1082 1090 doi:10.1002/hep.24452